DMAC: DiaMedica Pharma Company Value to Net Income

Corporate emblem and logo of DiaMedica Pharma (DMAC)

This daily price chart for DiaMedica Therapeutics (DMAC) reflects levels at -11.30, while the business relies on optimizing nephrology supply chains to protect margins. In drug development, DiaMedica Therapeutics (DMAC) is implementing automated synthesis, although final tests remain the responsibility of physicians. The asset's current valuation depends on the outcomes of late-stage trials for its post-stroke drug, as commercial revenue is currently absent.

DiaMedica Therapeutics Inc. (DMAC): P/E Multiple from 07/04/2022 to 11/17/2026

Analytical breakdowns for DiaMedica Therapeutics

- price and consensus price forecast:
- market capitalization information:
Summary company analysis:DMAC (DiaMedica Pharma)
Product sample of diamedica.com

The stability of DiaMedica Therapeutics (DMAC) is underpinned by the biomedical sector's low sensitivity to international conflicts and the humanitarian status of its products. Such neutrality minimizes operational risks, creating a reliable foundation for capitalization. The company's relative P/E ratio on GURU.Markets reflects the cost of each unit of profit, allowing for the determination of the current premium for protecting capital against inflation. The dynamics of this ratio serve as a signal for a timely exit from the asset before a potential market correction.